FUJIFILM Corp. is investing approximately $928 million in the Denmark site of FUJIFILM Diosynth Biotechnologies, a CDMO for biologics and advanced therapies. The investment will double the Denmark site’s current drug substance manufacturing capacity, and will expand capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.

The investment will expand production lines for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023. The development will also include the addition of the Denmark site’s first fill/finish production line (added by summer 2023), with a fully-automated system capable of producing up to approximately 35 million units per year for large-scale production. In spring 2022, a new packaging line equipped with facilities to assemble multiple types of auto-injectors as well as automatic labeling, will be added.

“Our culture of innovation and reputation of manufacturing excellence ensures our rapid growth to better serve the healthcare community,” said Takatoshi Ishikawa, executive vice president, general manager of bio-CDMO division, FUJIFILM Corporation. “Since the acquisition of the Denmark site last year, the facility’s strong manufacturing track-record, coupled with FUJIFILM Diosynth Biotechnologies’ technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion.”